Terns Pharmaceuticals
We have no price for Terns Pharmaceuticals since 15 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Terns Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$96.2 million of profit last year.
Terns Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Terns Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Terns Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -62 | -103 | -102 | -110 | |
| -61 | -102 | -101 | -110 | |
| -60 | -90 | -89 | -96 | |
| -1.67 | -1.27 | -1.12 | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 287 | 269 | 364 | 1,025 |
| Cash | 143 | 80 | 161 | 525 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 10 | 13 | 18 | 19 |
| 277 | 255 | 346 | 1,007 | |
| 36 | 71 | 80 | – | |
| -17.6% | -31.7% | -23.2% | -8.6% | |
| -21.8% | -35.3% | -25.7% | -9.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -49 | -67 | -70 | -82 | |
| 0 | 0 | 0 | – | |
| -49 | -67 | -70 | -82 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 26 | 16 | 13 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $55.56
- Range
- $35.00 – $70.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 30, 2026 | -0.25 | -0.29 | +13.8% |
| Nov 10, 2025 | -0.27 | -0.30 | +10.0% |
| Aug 5, 2025 | -0.26 | -0.28 | +7.1% |
| May 8, 2025 | -0.26 | -0.29 | +10.3% |
| Mar 20, 2025 | -0.24 | -0.30 | +20.0% |
| Nov 12, 2024 | -0.28 | -0.33 | +15.2% |
| Aug 5, 2024 | -0.31 | -0.35 | +11.4% |
| May 13, 2024 | -0.30 | -0.36 | +16.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Terns Pharmaceuticals
Is Terns Pharmaceuticals a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Terns Pharmaceuticals AI analysis
What does Terns Pharmaceuticals do?
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. It is in Biotechnology, based in Foster City, CA, United States, with 59 employees.
Does Terns Pharmaceuticals pay a dividend?
No. Terns Pharmaceuticals does not pay a dividend at the moment.
Who are Terns Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Terns Pharmaceuticals's.
Prices: daily closes to May 15, 2026. Fundamentals: company reports via invest-like data.